Personalized medicine in adult acute lymphoblastic leukemia

Haematologica

Volumn 100, Issue 7, 2015, Pages 855-858

  Hoelzer, Dieter ^a  

^a Onkologikum Frankfurt Am Museumsufer   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; ANTINEOPLASTIC AGENT; ASPARAGINASE; BCR ABL PROTEIN; BCR-ABL1 FUSION PROTEIN, HUMAN; CORTICOSTEROID; DASATINIB; PYRAZOLE DERIVATIVE; RUXOLITINIB; TUMOR MARKER; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CHROMOSOME TRANSLOCATION; DIAGNOSTIC ACCURACY; EDITORIAL; GENE EXPRESSION; GENETIC ANALYSIS; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PROGNOSIS; ADULT; AGED; B LYMPHOCYTE; DRUG EFFECTS; GENE TRANSLOCATION; GENETICS; METABOLISM; NEOPLASM, RESIDUAL; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROCEDURES; REMISSION; T LYMPHOCYTE;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASPARAGINASE; B-LYMPHOCYTES; BIOMARKERS, TUMOR; DASATINIB; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPHENOTYPING; NEOPLASM, RESIDUAL; PRECISION MEDICINE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYRAZOLES; REMISSION INDUCTION; T-LYMPHOCYTES; TRANSLOCATION, GENETIC; VINCRISTINE;

EID: 84936101906     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.127837     Document Type: Editorial

References (28)

1. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic Leukemia. J Clin Oncol. 2011;29(5):532-543.
2. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol. 2009;10(2):125-134.
3. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360(5):470-480.
4. Herold T, Baldus CD, Gökbuget N. Ph-like acute lymphoblastic leukemia in older adults. N Engl J Med. 2014;371(23):2235.
5. Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11):1005-1015.
6. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10(2):147-156.
7. Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantifıcation in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010;24(3):521-535.
8. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:7-12.
9. Beldjord K, Chevret S, Asnafi V, et al. Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123(24):3739-3749.
10. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868-1876.
11. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153-4162.
12. Ribera JM, Oriol A, Morgades M, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial. J Clin Oncol. 2014;32(15):1595-1604.
13. Hoelzer D, Gökbuget N. Change in prognostic factors. Leukemia Supplements 2012;1:1-2.
14. Ram R, Wolach O, Vidal L, Gafter-Gvili A, Shpilberg O, Raanani P. Adolescents and young adults with acute lymphoblastic leukemia have a better outcome when treated with pediatric-inspired regimens: systematic review and meta-analysis. Am J Hematol. 2012;87(5):472-478.
15. Gökbuget N. How I treat older patients with ALL. Blood. 2013;122(8):1366-1375.
16. Dombret H, Gabert J, Boiron JM, et al. Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group). Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia - results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357-2366.
17. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG 2993. Blood. 2009;113(19):4489-4496.
18. Pfeifer H, Goekbuget N, Völp C, et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2010;116:173 [Abstract].
19. Foà R, Vitale A, Vignetti M, et al. GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521-6528.
20. Cortes JE, Kim DW, Pinilla-Ibarz J, et al. PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
21. Hoelzer D. Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011: 243-249.
22. Kantarjian H, Thomas D, Wayne AS, O’Brien S. Monoclonal antibodybased therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012;30(31):3876–3883.
23. Hoelzer D, Walewski J, Döhner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124(26):3870-3879.
24. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol. 2012;13(4):403-411.
25. Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cellengaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–2498.
26. Topp MS, Gökbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57-66.
27. Russell Cruz, Bollard CM. T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect. Haematologica 2015;100 (6) 709-719.
28. Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5: (177):177ra38.